A once-promising Alzheimer's drug did not help
patients remember better or think more clearly, and the company said
Wednesday it had dropped plans to market it for people with mild
dementia.
The drug, called solanezumab, was designed to
clear the brain-clogging amyloid plaques that are one main physical
symptom of Alzheimer's. But patients with early dementia due to
Alzheimer's didn't seem to get much benefit from the drug, the company
that makes it said.
Click here for the full article.
No comments:
Post a Comment